Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Oncotype DX Stories

2012-03-22 12:40:21

Testing a breast cancer tumor for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, according to the results of a study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Thursday). Dr. Sabine Linn, an Associate Professor of Medical Oncology at The Netherlands Cancer Institute, Amsterdam, The Netherlands, will say that this is the...

2012-03-22 06:25:37

IRVINE, Calif. and AMSTERDAM, March 22, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that five-year follow-up data from the RASTER observational study indicates that its MammaPrint prognostic assay for breast cancer can help reduce adjuvant chemotherapy by 20 percent in patients deemed 'Low Risk.' From 2004 to 2006, the MircoarRAy PrognoSTics in Breast CancER study, known as RASTER, enrolled 427 women with primary breast carcinoma across...

2012-03-20 22:20:43

GENEVA, March 21, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of three new Oncotype DX® studies including data demonstrating the test's cost-effectiveness within the German and Hungarian healthcare systems, and Israeli data showing the test's impact on treatment decisions in early-stage invasive breast cancer patients with lymph-node positive status. These findings will be presented during poster sessions at the 8th European Breast Cancer Conference...

2012-02-06 15:02:00

REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced plans to establish a wholly owned subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions. The subsidiary is expected to be established by March 1, 2012 and provide its first commercial service in 2013. The new venture will be led by Randy Scott, who in...

2012-02-06 15:01:00

REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the year ended December 31, 2011. Total revenue for the year ended December 31, 2011 increased to $206.1 million, compared with $178.1 million in 2010, an increase of 16 percent. Product revenue was $204.8 million, compared with $174.9 million in 2010, an increase of 17 percent. Contract revenue comprised the balance of total revenue for...

2012-02-03 07:00:00

REDWOOD CITY, Calif., Feb. 3, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a large clinical study in prostate cancer evaluating the relationship of microRNAs, a novel class of biomarkers, to clinical outcomes for patients with early-stage prostate cancer. The data, presented at the 2012 Genitourinary (GU) Cancers Symposium, contribute to a greater understanding of prostate cancer biology by assessing the ability of specific microRNAs and genes...

2012-01-30 15:00:00

REDWOOD CITY, Calif., Jan. 30, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Monday, February 6 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2011 financial results. The call and webcast will follow the release of the fourth quarter financial results after market close. Conference Call Details To access the live conference call on February 6 at 4:30 p.m. Eastern Time via...

2012-01-26 20:41:00

MOUNTAIN VIEW, Calif., Jan. 26, 2012 /PRNewswire/ -- Pinpoint Genomics, Inc. today announced the publication of key data relating to its Pinpoint Dx Lung(TM) Assay in the journal The Lancet. The Pinpoint Dx Lung(TM) Assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer. The report in The Lancet describes the...

2012-01-26 06:00:00

QUEBEC CITY, Jan. 26, 2012 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company that develops and commercializes high value cancer diagnostic tests, today announced that its partner for the Previstage(TM) GCC Colorectal Cancer Staging Test, Signal Genetics, reported the results of a new study presented on January 21 at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, CA. The poster entitled "Guanylyl Cyclase C...

2012-01-23 09:00:00

NEW YORK, Jan. 23, 2012 /PRNewswire/ -- Signal Genetics, a privately held personalized medicine company focused on cancer, announced today the presentation of a paper entitled "Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis" at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, CA January 21, 2012. The data from the paper demonstrate the value of...